Showing results (181-190 of 226) with videos related to
Sort By:
Pageof 23
Lancet (London, England)|December 16, 1998
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study GroupA Mocroft, S Vella, T L Benfield, et al.Antiviral Research|September 7, 2000
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatmentS Vella, M C Galluzzo, G Giannini, et al.AIDS (London, England)|June 21, 2001
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsA I Veldkamp, G J Weverling, J M Lange, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthRory Chen, Vibeke S Catts, Ashleigh S Vella, et al.JAMA|April 17, 1998
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia StudyJ S Montaner, P Reiss, D Cooper, et al.Journal of Hepatology|February 1, 1997
Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infectionsM Angelico, E Renganathan, C Gandin, et al.Clinical and Experimental Immunology|April 12, 2001
Lack of evidence for the Th2 predominance in patients with chronic hepatitis CA Bergamini, F Bolacchi, G Cerasari, et al.Clinical and Experimental Immunology|April 12, 2001
Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis CA Bergamini, F Bolacchi, M Cepparulo, et al.AIDS (London, England)|October 9, 1998
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapyJ M Raboud, J S Montaner, B Conway, et al.AIDS (London, England)|December 2, 1998
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependentS Rae, J M Raboud, B Conway, et al.Pageof 23